DNA hypermethylation as an epigenetic mark for oral cancer diagnosis

Journal of Oral Pathology and Medicine

Volumn 40, Issue 9, 2011, Pages 665-676

  Radhakrishnan, Raghu ^a   Kabekkodu, Shamaprasad ^b   Satyamoorthy, Kapaettu ^b  

^a MANIPAL COLLEGE OF DENTAL SCIENCES   (India)

^b MANIPAL UNIVERSITY   (India)

Author keywords

DNA methylation; Global methylation; Methylated genes; Oral carcinogenesis

Indexed keywords

ATM PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; DIHYDROERGOTOXINE MESILATE; FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN MLH1; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P53; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; STRATIFIN; WNT PROTEIN;

APOPTOSIS; BLOOD GROUP ABO SYSTEM; CANCER DIAGNOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; DISEASE MARKER; DNA EXTRACTION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE CONTROL; HUMAN; MOUTH CANCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA REPAIR; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HUMANS; MOUTH NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 80053570233     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01055.x     Document Type: Review

References (110)

1. Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull WHO 1984; 62: 163-82.
2. Silverman S. Oral cancer. Hamilton, London: BC Decker, 1998.
3. Sankaranarayanan R. Oral Cancer in India; An epidemiologic and Clinical review. Oral Surg Oral Med Oral Pathol 1990; 69: 325-30.
4. Indian Council of Medical Research (ICMR). Annual reports of national cancer registry project of India. New Delhi: ICMR, 1982, 1984.
5. Scully C, Field JK, Tonkawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN). I. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 2000; 36: 256-63.
6. Jones PA. Epigenetics in Carcinogenesis and cancer prevention. Ann N Y Ac Sci 2003; 983: 213-9.
7. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999; 9: 40-8.
8. Baylin SB, Herman JG. DNA Hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-74.
9. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
10. Bird AP. The relationship of DNA methylation to cancer. Cancer Surv 1996; 28: 87-101.
11. Zingg JM, Jones PA. Genetic and Epigenetic aspects of DNA methylation on gene expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997; 18: 869-82.
12. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-13.
13. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261-82.
14. Lander ES, Linton LM, Birren B, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
15. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
16. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci 1993; 90: 11995-9.
17. Costello JF, Plass C. Methylation Matters. J Med Genet 2001; 38: 285-303.
18. Jaenisch R, Harbers K, Jahner D, Stewart C, Stuhlmann H. DNA Methylation, retroviruses and embryogenesis. J Cell Biochem 1982; 20: 331-6.
19. Shemer R, Razin A. Establishment of imprinted methylation patterns during development. In: Russo VEA, Martienssen RA, Riggs AD, eds. Epigenetic mechanisms of gene regulation. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1996; 215-29.
20. Widschwendter M, Jones PA. DNA Methylation and Breast Carcinogenesis. Oncogene 2002; 21: 5462-82.
21. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999; 286: 481-6.
22. Bestor T, Laudano A, Mataliano R, Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl- terminal domain of the mammalian enzymes is related to bacterial restriction methyl transferases. J Mol Biol 1988; 203: 971-83.
23. Bestor TH, Verdine GL. DNA Methyl transferases. Curr Opin Cell Biol 1994; 6: 380-9.
24. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (Cytosine - 5) methyltransferases. Nat Genet 1998; 19: 219-20.
25. Cravo M, Pinto R, Fidalgo P, et al. Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut 1996; 39: 434-8.
26. Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 1999; 85: 112-8.
27. Ehrlich M. DNA Methylation: normal development, inherited disease and cancer. J Clin Ligand Assay 2000; 23: 144-6.
28. Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science 1975; 187: 226-32.
29. Alves G, Tatro Fanning TG. Differential methylation of human line 1 retrotransposons in malignant cells. Gene 1996; 176: 39-44.
30. von Zeidler SV, Miracca EC, Nagai MA, Birman EG. Hypermethylation of the p16 gene in normal oral mucosa of smokers. Int J Mol Med 2004; 14: 807-11.
31. Lopez M, Aguirre JM, Cuevas N, et al. Gene promoter hypermethylation in oral rinses of leukoplakia patients - a diagnostic and/or prognostic tool? Eur J Cancer 2003; 39: 2306-9.
32. El Naggar AK, Lai S, Clayman G, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997; 151: 1767-74.
33. Huang MJ, Yeh KT, Shih HC, et al. The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int J Mol Med 2002; 10: 551-4.
34. Viswanathan M, Tsuchida N, Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003; 105: 41-6.
35. Kulkarni V, Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 2004; 40: 145-53.
36. Chang HW, Ling GS, Wei WI, Yuen AP. Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. Cancer 2004; 101: 125-32.
37. Nakahara Y, Shintani S, Mihara M, Ueyama Y, Matsumura T. High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas. Cancer Lett 2001; 163: 221-8.
38. Kresty LA, Mallery SR, Knobloch TJ, et al. Alterations of p16 (INK4a) and p14 (ARF) in patients with severe oral epithelial dysplasia. Cancer Res 2002; 62: 5295-300.
39. Sartor M, Steingrimsdottir H, Elamin F, et al. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer 1999; 80: 79-86.
40. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995; 55: 2988-94.
41. Mao L, Merlo A, Bedi G, et al. A novel p16INK4a transcript. Cancer Res 1995; 55: 2995-7.
42. Serrano M, Hannon G, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclinD/CDK4. Nature 1993; 366: 704-7.
43. Zhang Y, Xiong Y, Yabrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-34.
44. Papadimitrakopoulou V, Izzo J, Lippman SM, et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 1997; 14: 1799-803.
45. Cody DT II, Huang Y, Darby CJ, Johnson GK, Domann FE. Differential DNA methylation of the p16 INK4A/CDKN2A promoter in human oral cancer cells and normal human oral keratinocytes. Oral Oncol 1999; 35: 516-22.
46. Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 2001; 37: 498-504.
47. Lee JK, Kim MJ, Hong SP, Hong SD. Inactivation patterns of p16/INK4A in oral squamous cell carcinomas. Exp Mol Med 2004; 36: 165-71.
48. Soni S, Kaur J, Kumar A, et al. Alterations of Rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005; 68: 314-25.
49. Akanuma D, Uzawa N, Yoshida MA, Negishi A, Amagasa T, Ikeuchi T. Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncol 1999; 35: 476-83.
50. Timmermann S, Hinds PW, Munger K. Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene 1998; 17: 3445-53.
51. Motsch C, Giers A, Boltze C, et al. Biallelic inactivation of the p16-Gen in a metachronous triple carcinoma in the oropharyngeal region. Laryngorhinootologie 2004; 83: 55-60.
52. Kraunz KS, Hsiung D, McClean MD, et al. Dietary folate is associated with p16(INK4A) methylation in head and neck squamous cell carcinoma. Int J Cancer 2006; 119: 1553-7.
53. Tripathi Bhar A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol 2003; 129: 642-50.
54. Nakahara Y, Shintani S, Mihara M, Hino S, Hamakawa H. Detection of p16 promoter methylation in the serum of oral cancer patients. Int J Oral Maxillofac Surg 2006; 35: 362-5.
55. González MV, Pello MF, López-Larrea C, Suárez C, Menéndez MJ, Coto E. Deletion and methylation of the tumor suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997; 50: 509-12.
56. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL, Yuen AP. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 2003; 39: 1881-7.
57. Oshiro MM, Futscher BW, Lisberg A, et al. Epigenetic regulation of the cell type-specific gene 14-3-3 sigma. Neoplasia 2005; 7: 799-808.
58. Mhawech P. 14-3-3 proteins-an update. Cell Res 2005; 15: 228-36.
59. Nakajima T, Shimooka H, Weixa P, et al. Immunohistochemical demonstration of 14-3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage. Pathol Int 2003; 53: 353-60.
60. Gasco M, Bell AK, Heath V, et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 2002; 62: 2072-6.
61. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
62. Mattijssen V, Peters HM, Schalkwijk L, et al. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int J Cancer 1993; 55: 580-5.
63. Saito Y, Takazawa H, Uzawa K, Tanzawa H, Sato K. Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 5′ CpG island. Int J Oncol 1998; 12: 293-8.
64. Kudo Y, Kitajima S, Ogawa I, et al. Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 2004; 10: 5455-63.
65. Nakayama S, Sasaki A, Mese H, Alcalde RE, Tsuji T, Matsumura T. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int J Cancer 2001; 93: 667-73.
66. Yeh KT, Shih MC, Lin TH, et al. The correlation between CpG methylation on promoter and protein expression of E-cadherin in oral squamous cell carcinoma. Anticancer Res 2002; 22: 3971-5.
67. Chang HW, Chow V, Lam KY, Wei WI, Yuen A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002; 94: 386-92.
68. Chen Q, Lipkina G, Song Q, Kramer RH. Promoter methylation regulates cadherin switching in squamous cell carcinoma. Biochem Biophys Res Commun 2004; 315: 850-6.
69. Uesugi H, Uzawa K, Kawasaki K, et al. Status of reduced expression and hypermethylation of the APC tumor suppressor gene in human oral squamous cell carcinoma. Int J Mol Med 2005; 15: 597-602.
70. Gao S, Eiberg H, Krogdahl A, Liu CJ, Sørensen JA. Cytoplasmic expression of E-cadherin and beta-Catenin correlated with LOH and hypermethylation of the APC gene in oral squamous cell carcinomas. J Oral Pathol Med 2005; 34: 116-9.
71. Rasimas JJ, Kanugula S, Dalessio PM, Ropson IJ, Fried MG, Pegg AE. Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase. Biochemistry 2003; 42: 980-90.
72. Zang H, Fang Q, Pegg AE, Guengerich FP. Kinetic analysis of steps in the repair of damaged DNA by human O6-alkylguanine-DNA alkyltransferase. J Biol Chem 2005; 280: 30873-81.
73. Mikami T, Yoshida T, Numata Y, et al. Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors. Am J Clin Pathol 2007; 127: 366-73.
74. Murakami J, Asaumi J, Maki Y, et al. Influence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines. Oncol Rep 2004; 12: 339-45.
75. Rohatgi N, Kaur J, Srivastava A, Ralhan R. Smokeless tobacco (khaini) extracts modulate gene expression in epithelial cell culture from an oral hyperplasia. Oral Oncol 2005; 41: 806-20.
76. Kato K, Hara A, Kuno T, et al. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 2006; 132: 735-43.
77. Rodríguez MJ, Acha A, Ruesga MT, Rodríguez C, Rivera JM, Aguirre JM. Loss of expression of DNA repair enzyme MGMT in oral leukoplakia and early oral squamous cell carcinoma. A prognostic tool? Cancer Lett 2007; 245: 263-8.
78. Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004; 25: 2165-71.
79. Paradiso A, Ranieri G, Stea B, et al. Altered p16INK4a and FHIT expression in carcinogenesis and progression of human oral cancer. Int J Oncol 2004; 24: 249-55.
80. Baert-Desurmont S, Buisine MP, Bessenay E, et al. Partial duplications of the MSH2 and MLH1 genes in hereditary nonpolyposis colorectal cancer. Eur J Hum Genet 2007; 15: 383-6.
81. Liu K, Zuo C, Luo QK, Suen JY, Hanna E, Fan CY. Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn Mol Pathol 2003; 12: 50-6.
82. Sengupta S, Chakrabarti S, Roy A, Panda CK, Roychoudhury S. Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype. Cancer 2007; 109: 703-12.
83. Puri SK, Si L, Fan CY, Hanna E. Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am J Otolaryngol 2005; 26: 12-7.
84. Supić G, Kozomara R, Branković-Magić M, Jović N, Magić Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 2009; 45: 1051-7.
85. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21: 4231-6.
86. Araki D, Uzawa K, Watanabe T, et al. Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity. Int J Oncol 2002; 20: 355-60.
87. Oh HJ, Lee KK, Song SJ, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006; 66: 2562-9.
88. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002; 22: 4309-18.
89. Maruya S, Issa JP, Weber RS, et al. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 2004; 10: 3825-30.
90. Tran TN, Liu Y, TakaYgi M, Yamaguchi A, Fujii H. Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-associated oral carcinoma in a Vietnamese non-smoking/non-drinking female population. J Oral Pathol Med 2005; 34: 150-6.
91. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-56.
92. Cho KR, Fearon ER. DCC: linking tumor suppressor genes and altered cell surface interactions in cancer? Curr Opin Genet Dev 1995; 5: 72-8.
93. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002; 8: 3164-71.
94. Gao S, Worm J, Guldberg P, et al. Loss of heterozygosity at 9q33 and hypermethylation of the DBCCR1 gene in oral squamous cell carcinoma. Br J Cancer 2004; 91: 760-4.
95. Bolt J, Vo QN, Kim WJ, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 2005; 41: 1013-20.
96. Ai L, Vo QN, Zuo C, et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 2004; 13: 150-6.
97. Sherman JA, Partridge M. Expression of retinoic acid receptors in normal, dysplastic and malignant oral epithelia. Br J Oral Maxillofac Surg 1997; 35: 260-6.
98. Kao SY, Tu HF, Chang KW, Chang CS, Yang CC, Lin SC. The retinoic acid receptor-beta (RAR-beta) mRNA expression in the oral squamous cell carcinoma associated with betel quid use. Oral Pathol Med 2002; 31: 220-6.
99. Ralhan R, Chakravarti N, Kaur J, et al. Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. Int J Cancer 2006; 118: 1077-89.
100. Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 2004; 10: 1733-42.
101. McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res 2002; 62: 4757-66.
102. Dabelsteen E, Gao S. ABO blood-group antigens in oral cancer. J Dent Res 2005; 84: 21-8.
103. Gao S, Worm J, Guldberg P, et al. Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer 2004; 109: 230-7.
104. Worsham MJ, Chen KM, Meduri V, et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 668-77.
105. Righini CA, de Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 2007; 13: 1179-85.
106. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-5.
107. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61: 3419-24.
108. Ishida E, Nakamura M, Ikuta M, et al. Promoter hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol 2005; 41: 614-22.
109. Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR, Fan LP. Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep 2010; 24: 335-43.
110. Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14: 97-107.